Clinical trials are research studies that test new potential treatments for a disease. Talk to your doctor about possible clinical trials that could be helpful to you.
Glossary: HBV = Hepatitis B, CHB = Chronic hepatitis B, HDV = Hepatitis D, CHD = Chronic hepatitis D, ALT = Alanine aminotransferase, AST = Aspartate aminotransferase, EOT = End of Treatment, NTCP = Sodium/taurocholate cotransporting polypeptide, LNF-containing regimens = Lonafarnib-containing regimens
Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and ALT normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline. Contact: John Ferraro 650-272-6138 or DLIVR@eigerbio.com and refer to identifier NCT03719313.
Currently recruiting patients in:
- Miami, FL - University of Miami Schiff Center for Liver Disease. Contact: Katheryn Dae at 305-243-1104
- Norman, OK - Central Sooner Research. Contact: Kurt Smith at 405-329-0474 or email firstname.lastname@example.org
- Grafton, NZ - Auckland City Hospital. Contact: Faye Manu at 64 9 307 4949 or email Fayem@adhb.govt.nz
- 92 other international sites (not yet recruiting)
This study is designed to assess the long-term efficacy and safety of Bulevirtide in patients with HDV. Contact Dr. Yana Deloveri at +74957265253 or email email@example.com and refer to identifier NCT03852719.
Clinical trial sites to be announced
Projected clinical trial locations:
Multicenter, observational study (patients will not receive any treatment) that will build a registry of HDV patients around the world and collect clinical information. Contact: Dr. Heiner Wedemeyer at Wedemeyer.Heiner@mh-hannover.de or Dr. Svenja Hardtke at Hardtke.Svenja@mh-hannover.de and refer to identifier NCT02375906.
Currently recruiting patients in:
- Manaus, Brazil
- Rondonia, Brazil
- Berlin, Germany
- Hannover, Germany
- Larissa, Greece
- Karachi, Pakistan
- Ankara, Turkey
Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with ezetimibe may lead to decline in HDV levels. The aim of the study is to evaluate the utility of ezetimibe in patients with CHD. Contact: Zaigham Abbas at 922135862937 or email firstname.lastname@example.org and refer to identifier NCT03099278.
Evaluate, investigate and follow-up patients suffering from acute and chronic liver disease. Qualified patients may be able to participate in other offered studies. Contact Nancy Fryzek at 301-435-6122 email@example.com or Dr. T. Jake Liang at 301-496-1721 firstname.lastname@example.org and refer to identifier NCT00001971.
Clinical Trial Process
Learn more about all current HDV clinical trials.
www.clinicaltrials.gov is a service of the National Institutes of Health that provides a list of all the clinical trials that are being carried out in the United States. You can search for a clinical trial by disease, drug therapy, or trial location.
www.searchclinicaltrials.org offers a free search service by the Center for Information and Study on Clinical Research Participation (CISCRP) to help you find a clinical trial that may be right for you.
Hepatitis B Clinical Trials Page is a list that is updated each month by the Hepatitis B Foundation of clinical trials specific for hepatitis B.